​OVERVIEW

​The PCE Consortium’s Irritable Bowel Syndrome (IBS) Working Group was established to develop the following 3 PRO measures addressing the severity of IBS-C, IBS-D, and IBS-M for use in future irritable bowel syndrome trials. The DIBSS measures are available as:

• Diary for Irritable Bowel Syndrome Symptoms–Constipation (DIBSS-C)

• Diary for Irritable Bowel Syndrome Symptoms–Diarrhea (DIBSS-D)

• Diary for Irritable Bowel Syndrome Symptoms–Mixed (DIBSS-M)

 

PREFERRED TRANSLATION VENDOR FOR DIBSS-C, DIBSS-D, and DIBSS-M

FACITtrans

​

LICENSING
Licensing fees are assessed on a per trial/per measure basis for commercial use.​

• ​PCE Consortium Member Firms:

  • First Language​                                                                                           $1000 USD

  • Each Additional/Available Language                                                        $500 USD

• Non-Member Organizations​

  • First Language​                                                                                          $4000 USD

  • Each Additional/Available Language                                                      $2000 USD

 

Non-commercial use is assessed on a case-by-case basis for appropriateness and applicability.

​

To license an available version of the DIBSS-C, DIBSS-D, and/or DIBSS-M, please complete the licensing form. All of the information provided in the form will be kept strictly confidential. For questions about the measure, please contact us.

​

PUBLICATIONS

Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ, on behalf of the Critical Path Institute Patient-Reported Outcome Consortium’s Irritable Bowel Syndrome Working Group. Development of the Diary for Irritable Bowel Syndrome Symptoms (DIBSS) to assess treatment benefit in clinical trials: foundational qualitative research. Value in Health 2017;20:618-626. (https://doi.org/10.1016/j.jval.2016.11.001)

​

Coon CD, Hanlon J, Abel JL, Lundy JJ, Carson RT. Psychometric analysis of the abdominal score from the Diary for Irritable Bowel Syndrome Symptoms–Constipation using phase IIb clinical trial data. Value in Health 2020;23:362-369. (https://doi.org/10.1016/j.jval.2020.01.002)

​

McLeod L, Ervin C, Fehnel SE, Eremenco S, Carson RT, Hanlon J, Coons SJ, on behalf of the Patient-Reported Outcome Consortium’s Irritable Bowel Syndrome Working Group. Psychometric Evaluation of the Diary for Irritable Bowel Syndrome Symptoms-Constipation in a Prospective Observational Study. Value Health. 2024 May;27(5):614-622. doi: https://doi.org/10.1016/j.jval.2024.01.013 Epub 2024 Feb 2. PMID: 38311181.

​